NDC 69727-0002-1 HUMAN OTC DRUG

Drug Status:  Deprecated

Proprietary Name: Ultra Advantage

Drug Overview

The NDC Code 69727-0002-1 is assigned to “Ultra Advantage ” (also known as: “Abrotanum (artemisia Abrotanum), Anacardium Orientale, Fucus Vesiculosus, Helleborus Niger, Hypothalamus Suis, Lycopodium Clavatum, Thymolum, Thymus Serpyllum, Thyroidinum (bovine), Glandula Suprarenalis Suis, Hepar Suis, Pancreas Suis, Cinchona Officinalis, Graphites, Nicotinamidum, Baryta Carbonica, Calcarea Carbonica, Calcarea Phosphorica, Magnesia Phosphorica, Solidago Virgaurea”), a human otc drug labeled by “ELTTAC Inc DBA SWL”. The product's dosage form is liquid, and is administered via oral form.

Disclaimer

Do not rely on DataLabs to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of FDA-regulated products. We may limit or otherwise restrict your access to the API/WEB in line with our Terms of Service.

Drug Information
NDC Package Code	69727-0002-1
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Product NDC	69727-0002
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
11 Digit NDC Code	69727-0002-01
	It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format.
Proprietary Name	Ultra Advantage
	Also known as the trade name. It is the name of the product chosen by the labeler.
Non Proprietary Name	Abrotanum (artemisia Abrotanum) Anacardium Orientale Fucus Vesiculosus Helleborus Niger Hypothalamus Suis Lycopodium Clavatum Thymolum Thymus Serpyllum Thyroidinum (bovine) Glandula Suprarenalis Suis Hepar Suis Pancreas Suis Cinchona Officinalis Graphites Nicotinamidum Baryta Carbonica Calcarea Carbonica Calcarea Phosphorica Magnesia Phosphorica Solidago Virgaurea
	Sometimes called the generic name, this is usually the active ingredient(s) of the product.
Product Type Name	HUMAN OTC DRUG
	Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Labeler Name	ELTTAC Inc DBA SWL
	Name of Company corresponding to the labeler code segment of the ProductNDC.
Status	Deprecated
	Possible status values: Active Active NDC Code Deprecated Deprecated NDC Code Unfinished (Unapproved) The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved.

Route & Dosage
Dosage Form Name	LIQUID
	The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Route Name	ORAL
	The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Pharmaceutical Classes	BLOOD COAGULATION FACTOR [EPC], CALCIUM [CS], CALCULI DISSOLUTION AGENT [EPC], CATIONS, DIVALENT [CS], INCREASED COAGULATION FACTOR ACTIVITY [PE], INCREASED LARGE INTESTINAL MOTILITY [PE], INHIBITION LARGE INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], INHIBITION SMALL INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], MAGNESIUM ION EXCHANGE ACTIVITY [MOA], OSMOTIC ACTIVITY [MOA], OSMOTIC LAXATIVE [EPC], PHOSPHATE BINDER [EPC], PHOSPHATE CHELATING ACTIVITY [MOA], STIMULATION LARGE INTESTINE FLUID/ELECTROLYTE SECRETION [PE]
	These are the reported pharmaceutical class categories corresponding to the SubstanceNames listed above.

Substance & Strength
Substance Name	ARTEMISIA ABROTANUM FLOWERING TOP - 8 [hp_X]/mL SEMECARPUS ANACARDIUM JUICE - 8 [hp_X]/mL FUCUS VESICULOSUS (Substance Adverse Reports) - 8 [hp_X]/mL HELLEBORUS NIGER ROOT (Substance Adverse Reports) - 8 [hp_X]/mL SUS SCROFA HYPOTHALAMUS (Substance Adverse Reports) - 8 [hp_X]/mL LYCOPODIUM CLAVATUM SPORE (Substance Adverse Reports) - 8 [hp_X]/mL THYMOL (Substance Adverse Reports) - 8 [hp_X]/mL THYMUS SERPYLLUM (Substance Adverse Reports) - 8 [hp_X]/mL THYROID, BOVINE (Substance Adverse Reports) - 8 [hp_X]/mL SUS SCROFA ADRENAL GLAND (Substance Adverse Reports) - 8 [hp_X]/mL PORK LIVER (Substance Adverse Reports) - 8 [hp_X]/mL SUS SCROFA PANCREAS (Substance Adverse Reports) - 8 [hp_X]/mL CINCHONA OFFICINALIS BARK (Substance Adverse Reports) - 8 [hp_X]/mL GRAPHITE (Substance Adverse Reports) - 8 [hp_X]/mL NIACINAMIDE (Substance Adverse Reports) - 8 [hp_X]/mL BARIUM CARBONATE (Substance Adverse Reports) - 12 [hp_X]/mL OYSTER SHELL CALCIUM CARBONATE, CRUDE (Substance Adverse Reports) - 12 [hp_X]/mL TRIBASIC CALCIUM PHOSPHATE (Substance Adverse Reports) - 12 [hp_X]/mL MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE (Substance Adverse Reports) - 12 [hp_X]/mL SOLIDAGO VIRGAUREA FLOWERING TOP (Substance Adverse Reports) - 12 [hp_X]/mL
	This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Drug Package Information
NDC Package Code	69727-0002-1
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Package Description	30 ML IN 1 BOTTLE, SPRAY (69727-0002-1)
	A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE.
Sample Package	N
	Defines whether given package serves sample purposes.
Package NDC Exclude Flag	N
	This indicates whether the package has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.
Package Start Marketing Date	20181212
	This is the date that the labeler indicates was the start of its marketing of the drug package.
Package End Marketing Date	20261030
	This is the date the package will no longer be available on the market. If a package is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Packages that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Packages with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

Product Application & Marketing Information
Product NDC	69727-0002
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Application Number	N/S (NOT SPECIFIED)
	This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Marketing Category Name	UNAPPROVED HOMEOPATHIC
	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Listing Record Certified Through	N/S (NOT SPECIFIED)
	This is the date when the listing record will expire if not updated or certified by the firm.
Product Marketing Start Date	20181212
	This is the date that the labeler indicates was the start of its marketing of the drug product.
Product Marketing End Date	20261030
	This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Product NDC Exclude Flag	N
	This indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.

Tracking Information
Last Update Date	2026-11-03
	The date that a record was last updated or changed.